VenoVision selected for the Health Wildcatters 2022 Program in Texas to improve patient monitoring
Summary
VenoVision selected for the Health Wildcatters 2022 Program in Texas to improve patient monitoringFrom the Hebrew Universitys bench to bedsides in Dallas, TX, VenoVision brings cardiological expertise to non-invasive hemodynamic remote patient monitoring.Dallas, Texas, September 12, 2022: VenoVision was selected as one of only 11 start-ups from hundreds to participate in the Health Wildcatters 2022 Program.VenoVision will help improve therapeutic management, patient outcomes, and drive down the billions of dollars wasted every year on preventable perioperative deterioration and rehospitalization of those suffering, or at risk of, heart failure and other hemodynamic complications.VenoVision CSO, Prof. Yaakov Nahmias, said, "Our mission is to set a new frontier in contactless hemodynamic monitoring and accelerate the disruptive shift from conventional intervention techniques towards objective, non-invasive and continuous monitoring. Our point-and-press novel technology enables a whole new market of advanced low-cost monitoring for chronic patients living a life of misery without a real cure available."Prof. "Cardiac care is still one of THE top goals for any doctor and we are confident that Venovision will play an important role in improving patients lives", he said.VenoVision was conceptualized in The Hebrew Universitys BioDesign program, a multidisciplinary, team-based approach to medical innovation under the supervision of Prof. Yaakov Nahmias, Ph.D., Prof. Dan Galai, Ph.D., and Prof. Dr. Tal Hasin, MD. "With seed investment, mentorship and a tailored program, VenoVision will be working with Health Wildcatters to establish the core partnerships to initiate its milestone-based commercialization plan across product development, clinical and regulatory pathways.VenoVisionc/o Health Wildcatters3060 Pegasus Park Dr.Building 6, Ste 1104Dallas, TX 75247USAWebsite:Press Contact:Jonathan MaronCo-Founder, VenoVisionjmaron@kenes.com+972-54-940-9022About VenoVisionVenoVision will help improve therapeutic management, patient outcomes, and drive down the billions of dollars wasted on preventable deterioration and rehospitalization by supporting medical teams to non-invasively monitor and stabilize the hemodynamics of those suffering, or at risk of, heart failure and related complications. VenoVision is a low-cost, easy-to-use, contactless, deep-thermal imaging device and hemodynamic monitoring platform for the inpatient, outpatient and home environments.About Health WildcattersHealth Wildcatters is the top healthcare seed accelerator in the Southwest.